Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of NTQ5082 capsules versus eculizumab in paroxysmal nocturnal hemoglobinuria
CTR20254111Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of NTQ5082 in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Proportion of subjects achieving hemoglobin normalization without red blood cell transfusion. Started Nov 2025; status: completed.
02
Drugs
NTQ5082
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20254111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254111.